“VYXEOS is a valuable therapeutic option for patients with this complex, rapidly progressing blood cancer, and we are proud that its value has been recognised," said Eilis Quinn, the general manager of Jazz Pharmaceuticals for Australia and New Zealand.
'A valuable therapeutic option for patients with this complex, rapidly progressing blood cancer'
December 20, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech -
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech -
We know they're planning something on these issues, because they told us
November 18, 2025 - - Latest News